Huntington’s disease (HD) is an autosomal dominant hereditary disorder of the central nervous system. The disease results in progressive degeneration of the brain cells. A physician named George Huntington described the disorder in detail as hereditary chorea in 1872. Thus, earlier it was known as Huntington’s chorea or HC. Huntington’s disease usually develops symptoms in adulthood between the age of 30 years and 40 years. In case the symptoms of the disease are developed before the age of 20 years, it is referred as juvenile Huntington’s disease. Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.
The disease causes a wide range of symptoms in an affected person. Primarily, it leads to difficulty in motor control (movement), cognition (thinking), and behavior. Motor problems include impairments in voluntary movements as well as onset of uncontrolled involuntary jerking. People suffering from HD also have muscle problems such as muscle contracture (dystonia) or rigidity, impaired gait, posture, and balance. Loss of motor control hampers a person’s daily activities and causes difficulty in living a normal life. The disease also leads to speech and swallowing problems (dysphagia). These occur when the centers of the motor or cognitive control responsible for these functions are affected. A significant behavior and cognition disorder associated with Huntington’s disease is depression that results due to brain injury and loss of brain function.
Although medical science has no cure for this disease, the symptoms of this disease can be detected and treated. Drugs to treat movement disorders include tetrabenazine (Xenazine), antipsychotic drugs such as haloperidol (Haldol), chlorpromazine, and others. Antidepressants such as escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), citalopram (Celexa), and sertraline (Zoloft) are given as treatment. Development in scientific research has led to increased awareness about Huntington’s disease. This is one of the key drivers for the growth of the Huntington’s disease therapeutics market. In addition, increased prevalence of the disease is a key growth driver of the market. Unmet medical needs have driven scientists and researchers to develop therapy for Huntington’s disease, which in turn is likely to drive the global market. Increased investment by many pharmaceutical companies in the research and development sector to develop innovative and curative drugs for the disease is driving the growth of the global market. Further, alternative therapies, including speech therapy, psychotherapy, and physiotherapy, increase the potential of the market growth for Huntington’s disease therapeutics.
Geographically, the global Huntington’s disease therapeutics market is distributed over North America, Europe, APAC, and Latin America. North America dominates the global market due to increased awareness about the disease. In the North America market, the U.S. holds the largest market share, followed by Canada. Europe accounts for the second largest market globally. In Europe, countries such as France, Germany, the U.K., and Spain contribute major shares of the market. Increasing awareness about the disease along with growing infrastructure for scientific research is projected to lead to market establishment for Huntington’s disease therapeutics in other parts of the world such as China, India, Japan, Africa, Argentina, and Brazil.
Key players contributing highest market shares include Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Prana Biotechnology Ltd., Valeant Pharmaceuticals International Inc., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Raptor Pharmaceutical, Palobiofarma, and Ipsen.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.